Nektar Therapeutics (NKTR) News Today $0.64 +0.03 (+4.88%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$0.62 -0.01 (-1.79%) As of 04/17/2025 04:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Nektar Therapeutics (NASDAQ:NKTR) Coverage Initiated at StockNews.comStockNews.com initiated coverage on Nektar Therapeutics in a research note on Wednesday. They issued a "hold" rating on the stock.April 17 at 2:09 AM | marketbeat.comStockNews.com Begins Coverage on Nektar Therapeutics (NASDAQ:NKTR)April 16 at 2:11 AM | americanbankingnews.comNektar Therapeutics (NASDAQ:NKTR) Stock Rating Upgraded by Jefferies Financial GroupJefferies Financial Group raised Nektar Therapeutics from a "hold" rating to a "buy" rating and lifted their price target for the stock from $1.00 to $2.00 in a report on Friday.April 13, 2025 | marketbeat.comNektar management to meet virtually with B. RileyApril 12, 2025 | markets.businessinsider.comNektar Therapeutics (NKTR) Shares Surge on Jefferies UpgradeApril 12, 2025 | gurufocus.comNektar upgraded to Buy from Hold at JefferiesApril 11, 2025 | markets.businessinsider.comJefferies Upgrades Nektar Therapeutics to Buy, Doubles Price Target to $2.00April 11, 2025 | gurufocus.comNektar Therapeutics (NKTR) Gains After Jefferies UpgradeApril 11, 2025 | gurufocus.comNektar Therapeutics stock hits 52-week low at $0.44April 9, 2025 | investing.comEquities Analysts Set Expectations for NKTR Q1 EarningsNektar Therapeutics (NASDAQ:NKTR - Free Report) - Stock analysts at Zacks Research upped their Q1 2025 EPS estimates for shares of Nektar Therapeutics in a report issued on Wednesday, April 2nd. Zacks Research analyst K. Das now forecasts that the biopharmaceutical company will post earnings perApril 8, 2025 | marketbeat.comQ1 Earnings Estimate for NKTR Issued By Zacks ResearchNektar Therapeutics (NASDAQ:NKTR - Free Report) - Equities researchers at Zacks Research issued their Q1 2027 earnings per share (EPS) estimates for shares of Nektar Therapeutics in a research report issued to clients and investors on Wednesday, April 2nd. Zacks Research analyst K. Das forecastsApril 6, 2025 | marketbeat.comNektar Therapeutics (NASDAQ:NKTR) Receives Average Rating of "Buy" from BrokeragesNektar Therapeutics (NASDAQ:NKTR - Get Free Report) has earned an average rating of "Buy" from the seven analysts that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation, five have assigned a buy recommendation and one has given aMarch 31, 2025 | marketbeat.comTraders Buy Large Volume of Call Options on Nektar Therapeutics (NASDAQ:NKTR)Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) was the recipient of unusually large options trading activity on Friday. Traders acquired 2,351 call options on the stock. This represents an increase of approximately 245% compared to the typical volume of 681 call options.March 29, 2025 | marketbeat.comNektar files $300M mixed securities shelfMarch 29, 2025 | markets.businessinsider.comNektar Therapeutics files $300M mixed securities shelfMarch 28, 2025 | seekingalpha.comNektar Therapeutics (NKTR) Files $300M Mixed Securities Shelf OfferingMarch 28, 2025 | gurufocus.comPiper Sandler Remains a Buy on Nektar Therapeutics (NKTR)March 26, 2025 | markets.businessinsider.comNektar management to meet with Piper SandlerMarch 24, 2025 | markets.businessinsider.comNektar Therapeutics (NKTR): Among Stocks Wall Street Is Calling Bullish Amid Market TurmoilMarch 22, 2025 | insidermonkey.comPrimecap Management Co. CA Decreases Position in Nektar Therapeutics (NASDAQ:NKTR)Primecap Management Co. CA lowered its position in shares of Nektar Therapeutics (NASDAQ:NKTR - Free Report) by 6.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,540,386 shares of the biopharmaceuMarch 21, 2025 | marketbeat.comNektar Therapeutics to Participate in the H.C. ...March 20, 2025 | gurufocus.comNektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual ConferenceMarch 20, 2025 | prnewswire.comHC Wainwright Issues Positive Estimate for NKTR EarningsNektar Therapeutics (NASDAQ:NKTR - Free Report) - Equities researchers at HC Wainwright raised their Q1 2025 EPS estimates for shares of Nektar Therapeutics in a research report issued to clients and investors on Thursday, March 13th. HC Wainwright analyst A. He now anticipates that the biopharmaMarch 17, 2025 | marketbeat.comQ1 EPS Estimate for Nektar Therapeutics Boosted by AnalystNektar Therapeutics (NASDAQ:NKTR - Free Report) - William Blair lifted their Q1 2025 earnings per share estimates for shares of Nektar Therapeutics in a research report issued on Thursday, March 13th. William Blair analyst A. Hsieh now forecasts that the biopharmaceutical company will earn ($0.19March 17, 2025 | marketbeat.comOppenheimer Upgrades Nektar Therapeutics (NKTR)March 15, 2025 | msn.comNektar Therapeutics (NASDAQ:NKTR) Stock Rating Upgraded by OppenheimerOppenheimer raised Nektar Therapeutics from a "market perform" rating to an "outperform" rating and set a $6.00 price target on the stock in a report on Friday.March 15, 2025 | marketbeat.comWilliam Blair Sticks to Their Hold Rating for Nektar Therapeutics (NKTR)March 14, 2025 | markets.businessinsider.comNektar Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues LagMarch 14, 2025 | finance.yahoo.comNektar Therapeutics (NASDAQ:NKTR) Q4 2024 Earnings Call TranscriptMarch 14, 2025 | msn.comWilliam Blair Reiterates Market Perform Rating for Nektar Therapeutics (NASDAQ:NKTR)William Blair restated a "market perform" rating on shares of Nektar Therapeutics in a research note on Thursday.March 14, 2025 | marketbeat.comNektar Therapeutics (NASDAQ:NKTR) Given Buy Rating at HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $6.50 price target on shares of Nektar Therapeutics in a research report on Thursday.March 14, 2025 | marketbeat.comQ4 2024 Nektar Therapeutics Earnings CallMarch 13, 2025 | uk.finance.yahoo.comNektar upgraded to Outperform at Oppenheimer ahead of rezpeg readout in JuneMarch 13, 2025 | markets.businessinsider.comNektar up 12% to 91c after Oppenheimer upgrade with $6 targetMarch 13, 2025 | markets.businessinsider.comNektar Therapeutics (NASDAQ:NKTR) Releases Earnings Results, Beats Expectations By $0.33 EPSNektar Therapeutics (NASDAQ:NKTR - Get Free Report) issued its quarterly earnings data on Wednesday. The biopharmaceutical company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.33. Nektar Therapeutics had a negative return on equity of 173.28% and a negative net margin of 180.70%.March 13, 2025 | marketbeat.comNektar Therapeutics (NASDAQ:NKTR) Posts Quarterly Earnings Results, Beats Estimates By $0.33 EPSNektar Therapeutics (NASDAQ:NKTR - Get Free Report) released its earnings results on Wednesday. The biopharmaceutical company reported $0.15 EPS for the quarter, topping analysts' consensus estimates of ($0.18) by $0.33. Nektar Therapeutics had a negative net margin of 180.70% and a negative return on equity of 173.28%.March 13, 2025 | marketbeat.comNektar Therapeutics: Poised for Growth with Promising Rezpeg Study and Market PotentialMarch 13, 2025 | tipranks.comNektar Therapeutics (NKTR) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial ...March 13, 2025 | gurufocus.comQ4 2024 Nektar Therapeutics Earnings Call TranscriptMarch 13, 2025 | gurufocus.comNektar reports Q4 adjusted EPS (15c), consensus (19c)March 12, 2025 | markets.businessinsider.comNektar Therapeutics (NKTR) Q4 Earnings Beat EstimatesMarch 12, 2025 | msn.comNektar Therapeutics (NKTR) Q4 2024 Earnings Call TranscriptMarch 12, 2025 | seekingalpha.comNektar Therapeutics Reports Fourth Quarter and Full Year 2024 Financial ResultsMarch 12, 2025 | prnewswire.comNektar Therapeutics Q4 2024 Earnings PreviewMarch 11, 2025 | msn.comNektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2024 on Wednesday, March 12, 2025, After Close of U.S.-Based Financial MarketsMarch 5, 2025 | prnewswire.comNektar Therapeutics (NASDAQ:NKTR) Given Consensus Recommendation of "Moderate Buy" by BrokeragesNektar Therapeutics (NASDAQ:NKTR - Get Free Report) has earned an average rating of "Moderate Buy" from the seven analysts that are covering the firm, Marketbeat reports. Two analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy ratinMarch 5, 2025 | marketbeat.comAnalysts Conflicted on These Healthcare Names: Lemaitre Vascular (LMAT), Catalyst Pharma (CPRX) and Nektar Therapeutics (NKTR)February 28, 2025 | markets.businessinsider.comNektar completes enrollment in REZOLVE-AA Phase 2b trial of rezpegaldesleukinFebruary 26, 2025 | markets.businessinsider.comNektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AA Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Severe-to-Very Severe Alopecia AreataFebruary 26, 2025 | prnewswire.comWilliam Blair Reaffirms "Market Perform" Rating for Nektar Therapeutics (NASDAQ:NKTR)William Blair reiterated a "market perform" rating on shares of Nektar Therapeutics in a report on Tuesday.February 25, 2025 | marketbeat.com Get Nektar Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NKTR and its competitors with MarketBeat's FREE daily newsletter. Email Address NKTR Media Mentions By Week NKTR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NKTR News Sentiment▼0.370.53▲Average Medical News Sentiment NKTR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NKTR Articles This Week▼63▲NKTR Articles Average Week Get Nektar Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NKTR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies OMER News Today ASMB News Today CPIX News Today LLY News Today JNJ News Today ABBV News Today MRK News Today PFE News Today BMY News Today ZTS News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NKTR) was last updated on 4/19/2025 by MarketBeat.com Staff From Our PartnersGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredAmazon ShockerJeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nektar Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Nektar Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
